Description

• General description: Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
• Application: These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
• Biochem/physiol Actions: Mode of Action: Streptomycin acts by inhibiting prokaryote protein synthesis by binding to the S12 protein of the 30S ribosomal subunit, thus preventing the transition from imitation complex to chain-elongating ribosome. This causes miscoding or inhibits initiation.Mode of Resistance: A mutation in rpsL, a gene for S12 ribosomal protein, prevents binding of streptomycin to the ribosome. An aminoglycoside phosphotransferase also inactivates streptomycin.Antimicrobial spectrum: Streptomycin acts against gram-negative and gram-positive bacteria.
• Analysis Note: These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
• Other Notes: This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.